Esketemine, the ‘fast acting’ treatment for depression, could be approved for use in the UK in November – and is already sold in the US under the brand name Spravato.
Ketamine nasal spray could transform treatment of depression
Esketemine, the ‘fast acting’ treatment for depression, could be approved for use in the UK in November – and is already sold in the US under the brand name Spravato.